Form 4 for INKT MiNK Therapeutics, Inc.
Accepted 2025-09-11 00:00:00 ET · period of report 2025-09-09 · accession 0001193125-25-201376 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-11 | 2025-09-09 | INKT | Buell Jennifer | CEO | A - Grant | $15.36 | +18.2K | 41.9K | +77% | +$280.0K |
| D | 2025-09-11 | 2025-09-09 | INKT | Buell Jennifer | CEO | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-09 | A | A | 18,229 | $15.36 | 41,913 | D | — | — | (F1) Reflects the executive's 2024 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on October 9, 2025. (F2) $15.36 was the fair market value of MiNK Therapeutics, Inc. Common Stock on September 9, 2025, the stock issuance date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-09-09 | A | A | 50,000 | $0.00 | 50,000 | D | $15.36 · — to 2035-09-09 | 50,000 Common Stock | (F3) The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. |